Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FDA Accelerates Development of Novel Therapies for COVID-19https://www.bloomberg.com/press-releases/2020-04-07/fda-accelerates-development-of-novel-therapies-for-covid-19
U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus (COVID-19) Drug Development Efforts
https://apnews.com/press-release/pr-accesswire/507c8345cb7c99c01b817ed16d632809
https://www.bloomberg.com/press-releases/2020-04-07/fda-accelerates-development-of-novel-therapies-for-covid-19
They aren’t lying. NIH funds are also involved, here. They already submitted INDs with the FDA. “Consultants from the Biologics Consulting Group, Inc., Alexandria, VA, helped the Company develop the briefing documents including the presented clinical studies plan. Just be patient. “https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148249660
We’ll see. They won’t risk infringing on Remdesivir. This company found the process to outsmart the virus’ defenses. GOVX ALSO DID IT, BETTER THAN EVERYONE ELSE. Stay here and watch what is going to happen.
They know how to find the right ligands, game over. https://courses.lumenlearning.com/suny-wmopen-biology1/chapter/signaling-molecules-and-cellular-receptors/
HOW VIRUSES RECOGNIZE A HOST
“Unlike living cells, many viruses do not have a plasma membrane or any of the structures necessary to sustain life. Some viruses are simply composed of an inert protein shell containing DNA or RNA. To reproduce, viruses must invade a living cell, which serves as a host, and then take over the host’s cellular apparatus. But how does a virus recognize its host?
Viruses often bind to cell-surface receptors on the host cell. For example, the virus that causes human influenza (flu) binds specifically to receptors on membranes of cells of the respiratory system. Chemical differences in the cell-surface receptors among hosts mean that a virus that infects a specific species (for example, humans) cannot infect another species (for example, chickens).
However, viruses have very small amounts of DNA or RNA compared to humans, and, as a result, viral reproduction can occur rapidly. Viral reproduction invariably produces errors that can lead to changes in newly produced viruses; these changes mean that the viral proteins that interact with cell-surface receptors may evolve in such a way that they can bind to receptors in a new host. Such changes happen randomly and quite often in the reproductive cycle of a virus, but the changes only matter if a virus with new binding properties comes into contact with a suitable host. In the case of influenza, this situation can occur in settings where animals and people are in close contact, such as poultry and swine farms. Once a virus jumps to a new host, it can spread quickly. Scientists watch newly appearing viruses (called emerging viruses) closely in the hope that such monitoring can reduce the likelihood of global viral epidemics.“
That’s impossible. The technology is based on ligand production. This is is a very well known technology. The combined selection of ligands and drug fell right into their lap. They have the technology and the drug. Look: https://courses.lumenlearning.com/suny-wmopen-biology1/chapter/signaling-molecules-and-cellular-receptors/
NNVC SUCCESSFULLY UPDATED/ADVANCED TO ALL COVID-VARIANTS https://www.genengnews.com/covid-19-candidates/covid-19-keeping-an-eye-on/nanoviricides-2/
https://www.prnewswire.com/news-releases/nanoviricides-provides-update-on-its-pan-coronavirus-covid-19-drug-development-program-at-benzinga-healthcare-small-cap-conference-301392583.html
Be careful with the price spreads. Don’t buy on loose spreads over .01 differences with gaps. The spread prices should be tight to the penny, unless there is a rally.
NNVC Update on Pan-COVID-19 Drug Development
Highlights of the Presentation:
TWO Drug Candidates, NV-CoV-2 and NV-CoV-2-R in Development to Enter Clinical Trials
Both Possess Broad-Spectrum Activities Against Many Coronaviruses
Both Are Thus Expected to Continue to Work Against Variants
Even as SARS-CoV-2 Continues to Evolve with Increasing Resistance to Existing Drugs and Antibodies
Variants Would Therefore Not be Able to Escape Our Drugs, Particularly NV-CoV-2-R
Novel Mechanism of Action, Unlike Existing Drugs
NV-CoV-2-R is the Only Drug in Development with a Dual Mode of Action
Block Virus from Attacking Cells in the first place, and
Inhibit Virus Replication Inside Cells, Simultaneously
NV-CoV-2-R is the Only Drug in Development that Blocks the Complete Lifecycle of the Virus
NV-CoV-2 Component Neutralizes Virus Outside Cells Blocking Reinfection Cycle
Remdesivir Component Blocks the Replication Cycle Inside Cells
Makes it very difficult for virus to escape the drug
Animal Model Studies Have Indicated that Both NV-CoV-2 and NV-CoV-2-R are Substantially Superior to Remdesivir in Controlling Coronavirus Lethal Lung Infection
Lifespan Extension Over Untreated Infected Animals:
Remdesivir: 2.5 days (Only 50% Increase)
NV-CoV-2: 14 days (180% Increase)
NV-CoV-2-R: 16 days (220% Increase).
Both NV-CoV-2 and NV-CoV-2-R are Extremely Safe
NV-CoV-2 Well Tolerated at >3.3 g/kg Body Weight in Rats by I.V. Infusion
NV-CoV-2-R Well Tolerated at >1.8 g/kg Body Weight in Rats by I.V. Infusion
Anticipate Substantial Therapeutic Margin of Safety in Clinical Studies
Required GLP Safety/Toxicology Studies of NV-CoV-2 Completed
No Respiratory or Neurological Function Adverse Effects in a GLP Rat Neuro-Pulmonary Model Studies
No Cardiovascular Function Adverse Effects in a GLP Study in Cynomolgus Monkey (Non-Human Primate) Model
"Importantly, NV-CoV-2 can be administered orally, and was found to be effective given orally in an animal model," Dr. Diwan added, "Oral NV-CoV-2 should enable highly effective treatments for pediatric use, an urgent medical need that remains unmet with even the most talked about current drug developments".
Nanoviricides will have a cure, because their mechanism of action works with the simulated human receptors that they’re engineering their nanodrug-capsules with.
https://www.benzinga.com/node/23025282
https://www.biospace.com/article/strong-effectiveness-of-nanoviricides-drug-candidates-observed-in-an-animal-model-of-infection-by-an-ace2-using-human-coronavirus/
The animal tests proved that the simulated human receptors remained intact on the nano-capsules in animals. This absolutely guarantees that they will work in humans, also being the same geometry. The virus attaching to the simulated human receptors in animals, means that the virus will definitely attach to the engineered receptors in humans. Any overlap will be negated, because the nanoparticles will be accompanied and synergistically complimented with Remdesivir.
In addition, the level of plasma drug concentration increased and bioavailability was directly related with the same dose, because of the metabolic decrease. This means that smaller doses will have equal or greater effect, since they can calculate the plasma level concentration from subsequent dose ranges. This is amazing. And the virus doesn’t know the difference.
Human receptor shape remains intact and “VIRICIDAL!!!!!!” https://www.biospace.com/article/strong-effectiveness-of-nanoviricides-drug-candidates-observed-in-an-animal-model-of-infection-by-an-ace2-using-human-coronavirus/
https://www.benzinga.com/node/23025282
NANOVIRICIDES ENGINEERS EXACT CAPSULE RECEPTORS THAT WORK.https://www.biospace.com/article/strong-effectiveness-of-nanoviricides-drug-candidates-observed-in-an-animal-model-of-infection-by-an-ace2-using-human-coronavirus/
Rat testing doesn’t make any difference, here. This is not about species cell chirality of Remdesivir. This is about receptor protein The most important detail is that COVID Spike receptor was attracted to the NV-Cov-2-R receptor. This means the NV-Cov-2-R mechanism is effective. Remdesivir is FDA approved. And NV-Cov-2-R worked with Remdesivir, enhancing the plasma levels and reducing metabolic wasting. You can argue all you want. NV-Cov-2-R worked equal to or better than anticipated.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083867/
“Virus–receptor interactions play a key regulatory role in viral host range, tissue tropism, and viral pathogenesis. Viruses utilize elegant strategies to attach to one or multiple receptors, overcome the plasma membrane barrier, enter, and access the necessary host cell machinery. The viral attachment protein can be viewed as the “key” that unlocks host cells by interacting with the “lock”—the receptor—on the cell surface, and these lock-and-key interactions are critical for viruses to successfully invade host cells. Many common themes have emerged in virus–receptor utilization within and across virus families demonstrating that viruses often target particular classes of molecules in order to mediate these events. Common viral receptors include sialylated glycans, cell adhesion molecules such as immunoglobulin superfamily members and integrins, and phosphatidylserine receptors. The redundancy in receptor usage suggests that viruses target particular receptors or “common locks” to take advantage of their cellular function and also suggests evolutionary conservation. Due to the importance of initial virus interactions with host cells in viral pathogenesis and the redundancy in viral receptor usage, exploitation of these strategies would be an attractive target for new antiviral therapeutics.“
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765859/
“Binding affinity for a chiral drug can differ for diastereomers and between enantiomers. For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochemical information in structure libraries leading to a “coin toss” as to whether or not the “ideal” chiral structure is present.”
“The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compounds. These guidelines require that absolute stereochemistry be known for compounds with chiral centers and that this information should be established early in drug development in order that the analysis can be considered valid. From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance.“
NV-COV-2-R encapsulation enhances Remdesivir-plasma-concentration through slower metabolism. This increases bio-availability, demonstrating that smaller dosages of Remdesivir can be administered with greater efficacy and safety and less residual drug toxicity.
https://www.benzinga.com/node/23025282
“The animal study showed that almost double the remdesivir remained intact in plasma when given as the encapsulated NV-CoV-2-R form, compared to the standard remdesivir formulation in Sulfobutylether-ß-cyclodextrin sodium salt (SBECD), during the first day of dosing.
Additionally, remdesivir accumulation was observed on repeated dosing of NV-CoV-2-R.
After the fifth dose and following the standard remdesivir dosing pattern, the circulating level of remdesivir in plasma was 75% greater in the NV-Cov-2-R group than in the remdesivir group.
The increased intact circulating level did not increase toxicity.
These data demonstrate that the pan-coronavirus nanopviricide drug candidate NV-CoV-2-R minimizes the loss of remdesivir to bodily metabolism.”
Watch this:
Since this worked in rats, will work in humans. This is a very special case, because it is not testing the comprability of the rat and human cell interactions. What makes this even more special is that it not necessary to compare the compatibility of the rat and human cells. Here’s why: the only thing that is important for the test is the COMPATIBILITY OF THE NANOPARTICLE RECEPTOR WITH THE VIRUS RECEPTOR.
The virus thought that the particle was a rat cell and attached to it. (Coincidentally, rats also have the Covid receptor, because Covid infects animals and man and to and fro).
Once the virus attaches to the simulated particle receptor, it is doomed. That particle receptor matched the virus receptor. That is the most important result of the test.
So, all that’s needed, is to introduce the NNVC CAPSULE particles into a Covid infected human. I’m certain that the results will be equal or better than the rats. I can already see that it will work, because the particle is the same specification as the one tested in rats - - as long as COVID attaches to it. And it did. This will work. I am 1000% certain of the outcome. This is not about anything other than the compatibility of the nanoparticle. If the nanoparticle fit, the virus will be killed. We already know Remdesivir is effective. And we know this worked in Rats. That is a clear confirmation of success.
“Loud” doesn’t merely come close to amplifying the decibels. But my voice doesn’t come close to the decision makers decibels, amplified or not. But then again, you could be making some of those decisions too, in high decibles at greater magnitudes, by virtue. Either way, I love it. The universe is great. There is so much glory in the time, space and dimension of it all, that is literally kinetic, even at the microcosmic levels, the energy is perpetuating more energy from nothing. There’s energy in the core of the energies’ core that is amazingly creating its own energy. It just creating its own energy - - and this energy total comprises all of the micro, median and macro levels of different energy magnitudes. So just think of how long this energy has been creating its self, since what is commonly referred to as “the Big Bang (theory, because nobody can concretely prove it.” And yet, it is the only logical, “guess.” This is why the “first law of thermodynamics” states. It’s a fact. Then how is energy being created? When you decide to move, or write, or run, walk - - you get the idea? That resulting and expended energy “charging” the electrical impulses generated by our bodies, then where the fk is it coming and originating from. That is all energy, man; every bit of it - - from beginning to end, from charge to discharge, kinetic energy, whatever you refer to it by. That energy flow, from every discharge, no matter the magnitude, big or small, is emerging from somewhere. Now amplify that whole energy. It can be done, because we can also amplify the smallest. We can amplify the lightest sound and hear it from great distances. We have this technology. That means that we are doing this and amplifying small energies, too. Do you get the picture, all things being equal? We are alive and expending energy that we are creating. These energies are coming, right out of us - - everyone! Look around, hear, taste, smell, touch, see, build, construct, renew, architecture, everything - - look around. It’s all energy - - everything is charged and creating energies. Nothing escapes this process. It is inherent in every energy measure, atom, electron, orbital, dark matter, wherever! It’s happening in everything. It’s “fing” amazing and amazing. Or without any labels, speechless and indescribable.
Man, this stuff is right there with quantum physics and theory. I mean we are really creating energy, or it’s being created. Something caused the very first spark in the universe. It had to. It had to. There’s no other way to explain it. There isn’t. Because nobody, concretely, knows. The most amazing part of this is this. Nobody concretely knows. And yet, we know and feel that it’s happening. These energies are blooming all over the place, every moment, every second, every single to nano seconds, or smaller; It’s constant. This extends into the and, absolutely originating from the totals of energy created or transformed, but I have challenged the latter, since it is, somewhat, paradoxical.
But this seems very, merry, interesting, as it’s promised results. But what is even more interesting is the suspense. Will the energy reveal, acceptance, participation and encouragement forms of energies. Or will the energy reveal, bitterness, disdain or rejection type of energy? So, cynicism can be reality. But, the reality can also be the opposite of cynic’s perspective and energy.
Let the stones fall where they may. The energy of the universe is not in our control. So we cannot control, certain outcomes, outputs of energies. And there are also energies that we can control. Where did it all come from that is only amplifying?
It worked!! It worked!! EUREKA!
The receptors matched. This is huge!!!!!
NNVC receptors attracted the virus /with FDA approved Remdesivir. This is huge!!!! Their nanocapsule is effective and works. The receptors will work in humans, because it worked in Rats. This all comes down to a relation between the receptors and the spike protein. That’s it. Remdesivir is already FDA approved. It worked!!!
NNVC IS A WINNER! THEY GENIUSLY REPLICATED HOST RECEPTORS TO BIND AND KILL THE VIRUS IN A COUNTER ATTACK. THIS APPROACH WORKED IN PRECLINICAL STUDY AND IT WILL WORK IN HUMAN TRIALS, BECAUSE THE CAPSULE DID BIND WITH COVID. THE PRECLINICAL RAT STUDY PROVED THAT THE RECEPTOR SITES MATCH. REMDESIVIR IS ALREADY FDA APPROVED. THIS IS A WINNER BECAUSE IT FOCUSES ON RECEPTOR ACTIVATION. AND THE RECEPTORS MATCHED. COVID BINDED TO THE DRUG. THEY ALREADY SUCCEEDED.
https://www.benzinga.com/node/23025282
https://m.benzinga.com/article/19937727?utm_referrer=https%3A%2F%2Fm.benzinga.com%2Farticle%2F22925012%3Futm_referrer%3Dhttps%253A%252F%252Fm.benzinga.com%252Farticle%252F23025282%26utm_source%3Dhttps%253A%252F%252Fm.benzinga.com%252Farticle%252F23025282&utm_source=https%3A%2F%2Fm.benzinga.com%2Farticle%2F22925012%3Futm_referrer%3Dhttps%253A%252F%252Fm.benzinga.com%252Farticle%252F23025282%26utm_source%3Dhttps%253A%252F%252Fm.benzinga.com%252Farticle%252F23025282
The animal study showed that almost double the remdesivir remained intact in plasma when given as the encapsulated NV-CoV-2-R form, compared to the standard remdesivir formulation in Sulfobutylether-ß-cyclodextrin sodium salt (SBECD), during the first day of dosing.
Additionally, remdesivir accumulation was observed on repeated dosing of NV-CoV-2-R.
After the fifth dose and following the standard remdesivir dosing pattern, the circulating level of remdesivir in plasma was 75% greater in the NV-Cov-2-R group than in the remdesivir group.
The increased intact circulating level did not increase toxicity.
These data demonstrate that the pan-coronavirus nanopviricide drug candidate NV-CoV-2-R minimizes the loss of remdesivir to bodily metabolism.
Video:Nanoviricides replicates decoy-host-cell-protein countermeasures to trap viruses.
NIH is backing Nanoviricides and advancing Nano-medicine. Nanoviricides is advancing COVID drugs with Remdesivir as the only effective FDA, approved treatment. Nanoviricides will be filing for Emergency Use Authorization:
https://www.prnewswire.com/news-releases/nanomedicine-seen-as-a-promising-approach-for-diagnosis-and-treatment-against-covid-301131917.html
“The clinical candidate the Company has chosen is identified as NV-CoV-1-R. It is made up of a nanoviricide that we have found to possess broad-spectrum anti-coronavirus activity, now identified as NV-CoV-1, and remdesivir encapsulated inside the core of NV-CoV-1. NV-CoV-1 itself is designed to attack the virus particles themselves, and possibly would also attack infected cells that display the virus antigen S-protein, while sparing normal (uninfected) cells that do not display the S-protein. Additionally, remdesivir is widely understood to attack the replication cycle of the virus inside cells. Thus the combined attack enabled by NV-CoV-1-R on the virus could prove to be a cure for the infection and the disease, provided that the necessary dosage level can be attained without undue adverse effects. Human clinical trials will be required to determine the safety and effectiveness of NV-CoV-1-R.
Remdesivir is a well-known antiviral drug (developed by Gilead) that has been approved for emergency use treatment of SARS-CoV-2 infection or COVID-19 in several countries. NV-CoV-1 is a novel agent that is being used as an adjuvant to remdesivir in creating NV-CoV-1-R, to improve the overall effectiveness. It is well known that remdesivir suffers from rapid metabolism in circulation that breaks down the prodrug to its nucleoside form which is not readily phosphorylated. The Company anticipates that encapsulation in NV-CoV-1 may protect remdesivir from this rapid metabolism. If this happens, the effective level and stability of remdesivir in the body would increase. This increase may lead to increased effectiveness if there are no adverse effects. Such increased effectiveness, if found, may also allow reduction in the required dosage of remdesivir in the encapsulated form, i.e…”
The Company has accelerated its drug development program for COVID-19 with the goal of creating the most effective medicine to obtain regulatory approval for emergency use in the COVID-19 pandemic in the shortest timeline feasible, after achieving proof of concept of broad-spectrum anti-coronavirus effectiveness of test candidates. The Company therefore aggressively worked to harness the full power of the nanoviricides® nanomedicine platform to achieve these objectives.
“X60 supports any network, anywhere:”https://www.qualcomm.com/products/snapdragon-x60-5g-modem.
“Snapdragon X60 gives you a future-ready 5G phone for virtually any 5G network, anywhere.“
“low-latency 5G. X60 supports every available 5G network” and can take advantage of your carrier’s 5G advancements to bring you the fastest available 5G.”
https://www.qualcomm.com/products/snapdragon-x60-5g-modem
Wait until my next post: Amazing!!!
Waiting for lift off. https://www.tomsguide.com/news/iphone-13-release-date-price-specs-leaks
NEWS: https://www.notebookcheck.net/Qualcomm-Snapdragon-898-shows-up-on-Geekbench-for-the-first-time.558403.0.html
https://www.gsmarena.com/snapdragon_898powered_vivo_popsup_on_geekbench-news-50808.php
According to a previous leak, the Snapdragon 898 will feature a next-generation GPU (Adreno 730), a X65 5G modem (the first 10 Gbps modem), as well as upgraded ISP and NPU. Several Chinese makers are allegedly already testing the 898, so the first phones with the new chip should be unveiled not long after the chip itself.
The court settlement between Qual/App insures payments to Globalstar as royalty for spectrum use. Globalstar is receiving payment from Qualcomm, And Apple is paying Qualcomm for the chips.
Remove your stops. You won’t lose, here.
Globalstar is an investor’s dream company.
GAME OVER, SHORTS. GLOBALSTAR HAS WORLD ACCESS, NOW.
Globalstar will grow because of THIS—ONE customer.
I know who the customer is. It’s obvious.
Another Advance Payment Of $37.5M- -https://www.benzinga.com/news/21/09/22777367/globalstar-8-k-shows-co-received-added-advance-payment-of-37-5m-from-customer-co-to-use-proceeds-to - - From Customer, Co. To Use Proceeds To Repay Portion Of Outstanding Amount Under First Lien Credit Facility